Essex Investment Management Co. LLC lessened its stake in shares of BrainsWay Ltd. (NASDAQ:BWAY – Free Report) by 12.2% in the 4th quarter, Holdings Channel.com reports. The firm owned 305,446 shares of the company’s stock after selling 42,315 shares during the quarter. Essex Investment Management Co. LLC’s holdings in BrainsWay were worth $2,880,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other large investors have also modified their holdings of the stock. Rhumbline Advisers raised its stake in shares of BrainsWay by 10.8% during the fourth quarter. Rhumbline Advisers now owns 21,966 shares of the company’s stock worth $207,000 after purchasing an additional 2,144 shares during the last quarter. JPMorgan Chase & Co. raised its stake in shares of BrainsWay by 316.3% during the third quarter. JPMorgan Chase & Co. now owns 14,769 shares of the company’s stock worth $136,000 after purchasing an additional 11,221 shares during the last quarter. Finally, ARK Investment Management LLC purchased a new position in BrainsWay in the fourth quarter worth $1,656,000. Hedge funds and other institutional investors own 30.11% of the company’s stock.
Analyst Upgrades and Downgrades
Separately, HC Wainwright reiterated a “buy” rating and issued a $16.00 price objective on shares of BrainsWay in a research report on Monday, December 23rd.
BrainsWay Stock Performance
NASDAQ:BWAY opened at $9.41 on Friday. The stock has a fifty day moving average price of $10.21 and a two-hundred day moving average price of $9.55. The stock has a market capitalization of $177.16 million, a price-to-earnings ratio of 94.11 and a beta of 1.29. BrainsWay Ltd. has a 1 year low of $4.61 and a 1 year high of $11.79.
About BrainsWay
BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.
Recommended Stories
- Five stocks we like better than BrainsWay
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- Institutional Investors Bet $1B on These 4 Stocks—Should You?
- The Role Economic Reports Play in a Successful Investment Strategy
- One Must-Buy Stock and One to Avoid as Tariffs Shake the Market
- ESG Stocks, What Investors Should Know
- These 4 Tech ETFs Just Hit 50-Day Lows—Time to Buy?
Want to see what other hedge funds are holding BWAY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BrainsWay Ltd. (NASDAQ:BWAY – Free Report).
Receive News & Ratings for BrainsWay Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BrainsWay and related companies with MarketBeat.com's FREE daily email newsletter.
